Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in North America and Western Europe. This indolent malignancy is characterized by progressive expansion of the leukemic lymphoid clone, resulting in the accumulation of leukemia cells at the G 0 quiescent stage in bone marrow, blood, and other extramedullary sites such as spleen, liver, and lymph nodes. Failed programmed cell death (apoptosis) of the leukemia cells is currently considered to be the principal mechanism of pathogenesis of this disease. 1 The expansion of CLL cells impairs the normal function of bone marrow and the immune system and can ultimately lead to the death of the patients. In recent years, important progress has been made in understanding the biology and treatment of CLL (for review, see Refs 1 and 2). The nucleotide analog fludarabine (9-␤-D-arabinofuranosyl-2-fluoroadenine 5Ј-monophosphate, or F-ara-AMP) has emerged as an effective drug for the treatment of CLL. Currently, fludarabine-based chemotherapy is among the most effective therapeutic regimens for patients with CLL. [3] [4] [5] The overall response rates to fludarabine therapy approach 80% in previously untreated CLL patients and 50% in CLL patients who failed to respond to, or who relapsed from, previous treatment with other chemotherapeutic agents. 3, 6 The combination of fludarabine with granulocyte colony-stimulating factor (G-CSF) appears to significantly reduce myelosuppression and pneumonia in high-risk patients with CLL. 7 In patients with advanced refractory CLL who entered the group C protocol of the National Cancer Institute, the response rate was 32%. 8 Thus, the use of fludarabine in the treatment of CLL appears to be a significant advance in the therapy of this indolent malignancy.
Recent studies of the biochemical and molecular action of fludarabine have provided new insights into its mechanism of cytotoxicity. Fludarabine is transported into cells in its nucleoside form (9-␤-D-arabinofuranosyl-2-fluoroadenine, or F-ara-A) and is then converted by a series of cellular enzymes to the active metabolite F-ara-ATP, the triphosphate of fludarabine. In proliferating cells, F-ara-ATP is actively incorporated into DNA by DNA polymerases during replication. This incorporation causes termination of the daughter strand DNA synthesis at the sites of drug incorporation and is closely correlated with the drug's cytotoxic activity. 9 Further studies demonstrated that fludarabine kills leukemic cells by inducing apoptosis, and that drug incorporation into DNA is a critical event in triggering apoptotic cell death in proliferating cells. [10] [11] [12] Other pharmacological actions of fludarabine include inhibition of ribonucleotide reductase, DNA primase, and DNA ligase. [13] [14] [15] Furthermore, fludarabine is also incorporated into RNA and causes premature termination of the RNA transcripts. 16 Despite the identification of multiple targets for fludarabine action in proliferating leukemic cells, the precise mechanism by which fludarabine kills the indolent CLL cells remains unclear. CLL cells are mature in appearance but are biologically immature, and they characteristically express a number of B cell-associated markers. 17, 18 Because these cells are not active in DNA replication and therefore are unable to incorporate a significant amount of F-ara-AMP into cellular DNA, the terminal incorporation of fludarabine into DNA is unlikely to be the key mechanism responsible for the drug's cytotoxic action against CLL cells. Likewise, the inhibitory effect of fludarabine on DNA metabolism-related enzymes such as ribonucleotide reductase, DNA primase, and DNA ligase may not be the major mechanism of action in CLL cells.
Because all cells, either proliferating or quiescent, require active RNA transcription for the synthesis of housekeeping enzymes and other proteins essential for cell survival, inhibition of RNA synthesis may impose a lethal effect on quiescent cells. The objectives of the present study were to use pharmacological and biochemical approaches to investigate the effect of fludarabine on the synthesis of RNA and DNA in CLL cells, and to evaluate the relative contribution of each of these pharmacological actions to cytotoxicity in CLL cells. We demonstrated that although CLL cells incorporated detectable amounts of fludarabine into DNA through background DNA repair synthesis, suppression of this incorporation did not change the cytotoxic activity of fludarabine in CLL cells. In contrast, inhibition of RNA synthesis by fludarabine or other RNA synthesis inhibitors (␣-amanitin or actinomycin D) was closely correlated with cytotoxicity in CLL cells.
Materials and methods

Chemicals and reagents
F-ara-A, the dephosphorylated form of fludarabine (Berlex Laboratories, Alameda, CA, USA), was used for incubation in cell culture. Gemcitabine (dFdC) was provided by Lilly Research Laboratories (Indianapolis, IN, USA) 
Isolation of primary CLL cells from patients and cell culture
All patients in this study were diagnosed as having B cell CLL according to the National Cancer Institute (NCI) criteria for the diagnosis of CLL. 19 Co-expression of CD5 with B cell antigens and isotypic light chain was demonstrated in all cases. CLL cells were isolated from peripheral blood by density gradient centrifugation. Fresh blood (10 ml) samples were diluted with 3 volumes of cold (4°C) phosphate-buffered saline (PBS) and then layered over 10 ml of Ficoll-Hypaque mixture (specific gravity, 1.077 g/ml). After the samples were centrifuged at 400 g for 20 min, the buoyant layer containing leukemia cells was recovered, washed twice with sterile PBS, and resuspended in RPMI 1640 culture medium supplemented with 10% fetal bovine serum. The samples generally contained more than 90% lymphocytes. Unless otherwise indicated, all drug incubations were started after the cells were precultured in fresh medium for 20 h.
Examination of cell morphology and cell survival
After incubation of CLL cells with F-ara-A for various times, aliquots of cells were centrifuged on to glass slides, fixed with 100% methanol for 60 min, and air-dried briefly at room temperature. A second portion of the cells was processed for the DNA fragmentation assay as described below. The cells fixed on glass slides were stained with Wright-Giemsa stains, washed three times with PBS, and then washed three times with water. Cell morphology was examined and photographed by light microscopy using a Nikon HFX-II microscope. Cell survival was measured by color reaction with 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT assay). Unless otherwise indicated, CLL cells were first incubated with F-ara-A or other drugs for 24 h, washed with warm medium, and then incubated in drug-free medium in a 96-well plate (10 6 cells/200 l per well) for 72 h. MTT solution (3 mg/ml, 50 l) was added to each well, and the cells were incubated for an additional 4 h. After centrifugation, the cell pellets were dissolved in 200 l of dimethylsulfoxide. The optical density was determined with a micro-plate reader at 570 nm.
Incorporation of fludarabine into DNA
CLL cells were preincubated with 10 M deoxyadenosine (dAdo), 30 M dideoxycytidine (ddC), or no drug for 2 h and then labeled with [ 3 H]F-ara-A (10 M) for 10 h. The cells were washed with cold PBS and then lysed in buffer containing 10 mM Tris-HCl, pH 7.8, 100 mM NaCl, 25 mM EDTA, 0.5% SDS, and 0.1 mg/ml proteinase K. After the samples were digested at 50°C for 16 h, nucleic acids were precipitated with 2.5 volumes of 100% ethanol at −20°C overnight. RNA was removed from the samples by digestion first with RNase (DNase-free) and then with 0.5 N NaOH. After the samples were neutralized with perchloric acid (PCA), DNA was acidprecipitated with 0.4 N PCA and washed three times with 0.4 N PCA. Radioactivity associated with the DNA was measured by liquid scintillation counting. 
Assays
Analysis of cellular protein by SDS-PAGE
After CLL cells were incubated with drugs for the indicated times, the control or drug-treated cells were washed once with PBS at 4°C and then lysed in buffer containing 40 mM TrisHCl, pH 7.8, 2 mM EDTA, 1% Triton X-100, 0.2% SDS, 200 mM KCl, 1 g/ml leupeptin, 10 units/ml apotinin, and 0.2 mM PMSF. Cell debris and DNA bulk were removed by centrifugation at 17 000 g for 30 min at 4°C. The protein extracts (50 g/sample) were mixed with 1 volume of loading buffer (4 ×: 200 mM Tris-HCl, pH 6.8, 40% glycerol, 8% SDS, and 0.1% bromphenol blue), heated to 95°C for 5 min, and analyzed on a 10% SDS polyacrylamide gel. After electrophoresis, the gel was fixed and stained in solution containing 0.1% Coomassie blue, 50% methanol, and 5% acetic acid. A photograph was taken following washing the gel with solution containing 20% methanol and 1% acetic acid.
Results
When fresh leukemia cells isolated from patients with CLL were incubated with F-ara-A in vitro, the leukemia cells began to shrink and nuclear condensation was seen in 24 h, but apoptotic DNA fragmentation was barely detectable at this time. By 48 h, most of the cells became apoptotic bodies with the production of significant amounts of DNA fragments (data not shown). These results are consistent with our previous observations that fludarabine killed CLL cells by induction of apoptosis. 11, 22 However, the time required for fludarabine to induce apoptosis in CLL cells was much longer than that in proliferating leukemia cell lines, which usually undergo apoptosis several hours after exposure to nucleoside analogs. [10] [11] [12] These observations suggest the possibility that the biochemical pathway or mechanism by which fludarabine induces apoptosis in quiescent CLL cells may be different from that in proliferating leukemia (CEM) cells, in which the incorporation of the drug molecules into cellular DNA is the key mechanism of cytotoxicity. 10 Because fludarabine inhibits both RNA and DNA synthesis in proliferating leukemic cells, it is important to examine the effects of fludarabine on the synthesis of both types of nucleic acids in CLL cells and to determine which of these inhibitions is critical in causing cell death. Freshly isolated CLL cells were incubated with various concentrations of F-ara-A for 20 h and then labeled either with H]uridine to measure the RNA synthesis activity or with [5- 3 H]deoxycytidine to measure the DNA synthesis activity. Although peripheral CLL cells are quiescent and are not active in DNA replication, they still maintain an active DNA repair capacity to respond to DNAdamaging factors such as free radicals produced by cellular metabolism. [ 3 H]Deoxycytidine, a relatively specific precursor for DNA repair synthesis, 20 was used to detect this activity. As illustrated in Figure 1a , incorporation of H]uridine into the RNA of CLL cells was inhibited by F-ara-A in a concentration-dependent manner (1-10 M). The concentration required to reduce 50% RNA synthesis activity was approximately 10 M. A dose-dependent decrease of cell survival, as determined by MTT assay, was observed within the range of F-ara-A concentrations tested (1-10 M, Figure 1c) . The loss of cell survival seemed to be correlated with inhibition of RNA synthesis. However, these concentrations of F-ara-A also potently inhibited DNA repair synthesis in CLL cells ( Figure  1b) .
Several strategies were used to further evaluate the role of inhibition of RNA and DNA synthesis by fludarabine in causing cytotoxicity in CLL cells. First, dideoxycytidine (ddC), a known inhibitor of the DNA repair enzyme pol ␤, 23, 24 was used to inhibit DNA repair synthesis in CLL cells in the presence and absence of F-ara-A. Addition of 30 M ddC reduced the repair synthesis by approximately 80% (Figure 2a) , whereas cell survival was not affected by this drug concentration (Figure 2b ). In contrast, 10 M F-ara-A reduced DNA repair synthesis by about 75% and also reduced cell survival by more than 50% (Figure 2 ). These results suggest that a mechanism other than inhibition of DNA repair synthesis was responsible for the observed cytotoxicity in CLL cells. The combination of ddC and F-ara-A did not enhance the cytotoxic activity of F-ara-A in CLL cells (Figure 2b ). When aphidicolin, another inhibitor of DNA polymerases, was used to inhibit DNA repair synthesis in CLL cells, similar results were observed. For example, 4 M aphidicolin inhibited [ 3 H]deoxycytidine incorporation by 30-50% without reducing cell survival; the combination of aphidicolin and 10 M F-ara-A did not enhance the cytotoxic effect of F-ara-A (data not shown). These results again suggest that inhibition of DNA synthesis in CLL cells may not be the key event in causing cell death.
Because the incorporation of fludarabine into cellular DNA
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Figure 1
Effect of F-ara-A on RNA and DNA synthesis activity and cell survival. CLL cells were incubated with the indicated concentrations of F-ara-A for 20 h followed by a 4 h pulse with H]uridine (2 Ci/ml) or [5- 3 H]deoxycytidine (2 Ci/ml) to measure the synthesis activity of RNA (a) or DNA (b) as described in Materials and methods. Another portion of the cells was washed free of drug and incubated in drug-free medium for an additional 72 h. Cell survival was measured by MTT was previously shown to be a critical event in causing cytotoxicity in proliferating cells, 9, 10 we quantified the amount of drug incorporation into DNA in CLL cells in the presence and absence of ddC or deoxyadenosine, which competes with Fara-A at both intracellular phosphorylation and DNA incorporation steps. The relationship between drug incorporation and cytotoxicity was evaluated under these conditions. As shown in Figure 3a , ddC (30 M) and deoxyadenosine (10 M) each reduced fludarabine incorporation into DNA by more than 50%. However, this reduction of fludarabine incorporation did not result in a decrease of cytotoxicity ( Figure  3b, solid bars) . For instance, 10 M F-ara-A reduced cell survival by about 60%; the same degree of cytotoxicity was seen when F-ara-A was combined with ddC or deoxyadenosine, although F-ara-A incorporation into DNA was reduced by more than 50%. Neither ddC nor deoxyadenosine alone exhibited significant cytotoxicity (Figure 3b , hatched bars). These data suggest that incorporation of fludarabine into DNA may not be critical for causing cytotoxicity in CLL cells.
To evaluate the role of RNA synthesis inhibition in killing CLL cells, we used ␣-amanitin, an inhibitor of RNA polymerases without affecting DNA synthesis, to block RNA synthesis in CLL cells and then determined its correlation with cytotoxicity. As shown in Figure 4a , ␣-amanitin inhibited RNA synthesis in CLL cells in a concentration-dependent manner; the inhibition of RNA synthesis was associated with a proportional loss of cell survival (Figure 4b ). When cell survival was plotted against inhibition of RNA synthesis and analyzed by linear regression (Figure 4c ), there was a significant linear correlation between these two parameters (r = 0.973, P Ͻ 0.0001). Thus, it appears that inhibition of RNA synthesis was an important event in causing cytotoxicity in CLL cells. In contrast, when CLL cells were incubated with gemcitabine, an anticancer drug that mainly inhibits DNA synthesis with minimal effect on RNA, 25 only moderate cytotoxicity was observed at relatively high drug concentrations (10-100 M), although DNA repair synthesis was severely inhibited at these concen- trations (data not shown). These data further suggest that inhibition of DNA synthesis may not be an important cytotoxic mechanism in CLL cells.
Actinomycin D is a relatively specific inhibitor of RNA synthesis when used at low concentrations. 26 We used this compound to further evaluate the role of RNA synthesis inhibition in causing cytotoxicity in CLL cells. As shown in Figure 5a , actinomycin D at the concentrations of 1 and 10 ng/ml inhibited [ 3 H]uridine incorporation by 20% and 70%, respectively. This inhibition of RNA synthesis was associated with a proportional decrease in cell survival as measured by MTT assay (Figure 5b ). The combined use of actinomycin D (1 or 10 ng/ml) and F-ara-A (3 or 10 M) had an additive inhibitory effect on both RNA synthesis and cell survival. These results are consistent with the experiments in which CLL cells were incubated with ␣-amanitin, and further support the hypothesis that inhibition of RNA synthesis in CLL cells is a critical cytotoxic event.
Because the synthesis of cellular protein depends on the presence of functional mRNA transcripts as the templates for translation, it is logical to speculate that inhibition of RNA synthesis by fludarabine may lead to a decrease in protein Effect of ␣-amanitin on RNA synthesis in CLL cells and its correlation with cell survival. CLL cells were treated with various concentrations of ␣-amanitin for 20 h followed by a 4 h pulse with cells after incubation with F-ara-A was likely secondary to the inhibition of RNA synthesis.
If the reduction of protein synthesis was the consequence of depletion of RNA templates, one would expect that proteins translated from short half-life mRNA would be more significantly affected than the proteins coded by stable mRNA transcripts. To test this possibility, protein extracts from CLL cells incubated with F-ara-A for various times were analyzed by SDS polyacrylamide gel electrophoresis. As illustrated in Figure 6b , no apparent changes in protein bands were seen after 24 h incubation with F-ara-A (compare lanes 1 and 2). Prolonged drug incubation (48 h) resulted in the disappearance of certain protein bands (compare lanes 4 and 5). The most prominent missing band was located approximately at the 50 kDa region (indicated by the arrow). A close inspection of the protein bands revealed that a few minor bands were also missing from the 70-130 kDa region in the 48 h sample (lane 5) but still remained in the 24 h sample (lane 2). Because the disappearance of the 50 kDa protein band was most prominent in the F-ara-A-treated sample, we speculate that this protein might be a relatively fast-turnover molecule and blocking protein synthesis should also lead to the depletion of this protein. As shown in Figure 6b (lane 3) , incubation of CLL cells with 5 g/ml puromycin (a protein synthesis inhibitor) for 24 h led to a preferential depletion of the 50 kDa protein and several other protein bands in the 70-130 kDa region (lanes 3 and 7). This concentration of puromycin caused an almost complete loss of cell survival (data not shown). A lower concentration (1 g/ml) of puromycin did not cause the loss of the 50 kDa protein (lane 6) and only led to a minimum decrease of cell survival being observed (Figure 7) . Interestingly, incubation of CLL cells with 10 M F-ara-A and 1 g/ml puromycin for 24 h resulted in a depletion of the 50 kDa protein (Figure 6b, lane 9) . Neither drug alone led to a detectable change of this protein (lanes 2 and 6).
It appears that the combination of an RNA synthesis inhibitor (F-ara-A) and a protein synthesis inhibitor (puromycin) was able to synergistically deplete the 50 kDa protein. We further investigated the possibility of using this drug combination to enhance the killing of CLL cells. Fresh CLL cells were incubated with 10 M F-ara-A in the presence and absence of 1 g/ml puromycin for 24 h, washed, and incubated in fresh medium for an additional 72 h. Cell survival was then measured by MTT assay. As shown in Figure 7 , incubation of fresh CLL cells treated with 10 M F-ara-A or 1 g/ml puromycin decreased cell survival to 30% and 80% of the control value,
Figure 7
Effect of F-ara-A, puromycin, and cycloheximide on the survival of CLL cells in vitro. Fresh CLL cells were incubated with Fara-A (10 M), puromycin (1 g/ml), cycloheximide (5 g/ml), or the indicated combinations for 24 h. The cells were washed free of drugs and then incubated in fresh medium for an additional 72 h. MTT assay was performed as described in Materials and methods. Values are means ± s.e. for seven to eight separate experiments.
respectively. Combination of the two drugs reduced cell survival to 12% of the control value. Thus, the observed cytotoxic effect of F-ara-A and puromycin was greater than the predicted additive value (0.3 × 0.8 = 0.24). However, combination of F-ara-A and cycloheximide, another inhibitor of protein synthesis, appeared to have an additive cytotoxic effect in CLL cells (Figure 7 ).
Discussion
Several lines of evidence in the present study suggested that inhibition of RNA synthesis may be an important biochemical mechanism in fludarabine-induced cytotoxicity in CLL cells. First, the degree of RNA synthesis inhibition by fludarabine in CLL cells was closely correlated with the loss of cell survival (Figure 1 ). In the experiments using ␣-amanitin, whose primary action is inhibition of RNA polymerase, there was a linear correlation between inhibition of RNA synthesis and loss of cell survival (r = 0.973, P Ͻ 0.0001; Figure 4c ). Second, although Figure 1 also shows that DNA synthesis was inhibited by fludarabine in a concentration-dependent manner, it appears that this inhibition merely reflected another aspect of fludarabine action rather than a lethal event in CLL cells. For instance, suppression of fludarabine incorporation into DNA by dideoxycytidine or deoxyadenosine did not alter the cytotoxicity of fludarabine (Figure 3) . Third, compounds that mainly inhibit RNA synthesis with no significant effect on DNA synthesis showed potent cytotoxic effect in CLL cells, as illustrated by the experiments with ␣-amanitin and low concentrations of actinomycin D (Figures 4 and 5) . Finally, drugs that primarily affect DNA synthesis with minimal effect on RNA synthesis (gemcitabine and aphidicolin) were not effective in killing CLL cells. Thus, it appears that incorporation of fludarabine into DNA and its effect on DNA synthesis may not be critical in causing cytotoxicity in CLL cells. However, it should be pointed out that fludarabine is a potent inhibitor of DNA repair synthesis, combination of this drug with other DNA damaging agents may provide a different strategy to kill cancer cells. [27] [28] [29] Furthermore, because fludarabine is an effective DNA chain terminator, it is important to evaluate the activity of this drug in primary leukemia cells from patients with AML, CML, and ALL. Termination of DNA synthesis is expected to play an important role in causing cytotoxicity in leukemia cells with significant proliferating population. Thus, fludarabine may act by several mechanisms, and the importance of each is likely to be dependent upon the biological context of the cancer cells.
It is of interest to note that although 3 M fludarabine and 1 ng/ml actinomycin D inhibited RNA synthesis to a similar degree (about 80% of the control, as measured by [ 3 H]uridine incorporation), fludarabine was more toxic than actinomycin D ( Figure 5 ). This apparent discrepancy in the extent of RNA synthesis inhibition and cytotoxicity is likely due to the differences in the mechanisms of action of actinomycin D and fludarabine. Because the incorporation of fludarabine into RNA causes a premature termination of the transcripts 16, 30 and the truncated RNA still contains [ 3 H]uridine, the percentage of functional full-length RNA is likely to be less than the percent of overall remaining [ 3 H]uridine incorporation. In contrast, the action of actinomycin D, which intercalates in DNA and physically obstructs the transcriptional complex, at minimally active concentrations (inhibited less than 20% overall RNA synthesis) may only retard the transcription process, thus allowing full-length transcripts to be produced. Thus, even though the overall decrease in [
3 H]uridine incorporation may be the same, the actions of each inhibitor would have different effects on the functional full-length mRNA. This could lead to the appearance that similar inhibition of overall [ 3 H]uridine incorporation by fludarabine and actinomycin D resulted in a different degree of cytotoxicity. It is also possible that other mechanisms, in addition to inhibition of RNA synthesis, may also be involved in fludarabine-induced cytotoxicity. For instance, the triphosphates of fludarabine (F-ara-ATP) and 2-chlorodeoxyadenosine (2-CdATP) have been shown to trigger apoptosis through the activation of apaf-1/caspase cascades. 31 It has been reported that CLL cells with mutated p53 may be more resistant to fludarabine, 32 whereas other studies suggest that the p53 status may not be a critical determinant of sensitivity of CLL to fludarabine. 33 At the present time, there is not evidence that indicates a direct link between RNA synthesis inhibition by fludarabine and p53 signaling. One possibility is that termination of RNA transcription by fludarabine may serve as an initial signal to activate the p53-dependent apoptosis pathway. A detectable background DNA repair synthesis activity was demonstrated by [ 3 H]deoxycytidine incorporation in CLL cells (Figure 1b) . Thus, it is also possible that inhibition of RNA synthesis might disrupt the transcriptionally coupled repair of DNA damage, which might then trigger the p53-dependent apoptotic cell death program. Further studies are needed to investigate these possibilities.
2-Chlorodeoxyadenosine is another nucleoside analog that shows a potent activity against CLL cells in vitro 22 and in the clinic. 34 Previous studies demonstrated that this drug, like fludarabine, inhibits DNA synthesis by inhibition of ribonucleotide reductase and by incorporation into DNA in proliferating cells. [35] [36] [37] It was also shown that the triphosphate of 2-chlorodeoxyadenosine (2-CdATP) is able to induce apoptosis by activating the apaf-1/caspase cascade. 31 The effect of 2-chlorodeoxyadenosine on RNA synthesis, however, has not yet been clearly defined. In a separate study, we demonstrated that a 10 h incubation of CLL cells with 5 M chlorodeoxyadenosine inhibited RNA synthesis by 35% (data not shown). It is not yet known whether chlorodeoxyadenosine triphosphate is inhibitory to mammalian RNA polymerases or whether the drug is incorporated into RNA in CLL cells. An in vitro study Leukemia by Hentosh and Tibudan 37 suggested that when the nucleotide of chlorodeoxyadenosine was incorporated into DNA, it hampered the function of the DNA as a template for RNA transcription.
Our studies in vitro indicated that fludarabine inhibited RNA synthesis by incorporation into the RNA transcripts, which were then prematurely terminated. 16 In proliferating leukemia cells (CEM), this drug was preferentially incorporated into mRNA with about 80% of the incorporated drug molecules located at the 3Ј ends of the mRNA transcripts. Furthermore, the prematurely terminated mRNA lost its function as a template for protein synthesis. 16 On the basis of these observations, we hypothesized that the inhibition of RNA synthesis by fludarabine in CLL cells may eventually deplete functional mRNA and subsequently decrease protein synthesis. The facts that short-term (3 h) incubation of CLL cells with fludarabine did not significantly affect overall protein synthesis activity, and that longer incubation (24 h) was needed to reduce [ 3 H]leucine incorporation ( Figure 6a ) are consistent with this hypothesis. Although RNA synthesis may be inhibited shortly after cells are exposed to fludarabine, the pre-existing RNA in the cells may still be able to support protein synthesis for a certain period. Thus, RNA with a relatively short elimination time would be affected by fludarabine to a much greater extent than the RNA transcripts with slow turnover rates.
It is important to note that a general (or global) inhibition of RNA synthesis by fludarabine led to a preferential depletion of certain protein molecules in CLL cells (Figure 6b ). The biochemical mechanism responsible for this phenomenon is probably due to the different elimination rates for different mRNA and protein molecules in the cells. If a short-lived protein is also encoded by a short-lived mRNA, this particular protein molecule would most likely be depleted by fludarabine treatment. The preferential depletion of short-lived mRNA may also explain why only a moderate reduction (20-30%) of the overall [ 3 H]leucine incorporation was observed when CLL cells were incubated with fludarabine. The pre-existing mRNA in the cells was still able to support most of the cellular protein synthesis. Because certain protein molecules can be severely depleted even when the overall protein synthesis activity is only moderately reduced, it is important not to underestimate the biological significance of a partial inhibition of protein synthesis. For instance, if a critical survival factor is depleted, the cells are likely to die despite the continued synthesis of other proteins. In fact, inhibition of synthesis of the short half-life mRNA for IL-2 and its receptor has been suggested to be a mechanism of fludarabine-induced apoptosis in T lymphocytes. 38 If the depletion of short-lived proteins required for the survival of CLL cells is a biochemical approach to killing the leukemia cells, one would expect that a direct inhibition of protein synthesis, rather than an exhaustion of the RNA templates, may also have a potent cytotoxic effect on CLL cells. Thus, inhibition of protein synthesis may serve as a new mechanism for the design of therapeutic strategies for CLL. In fact, Collins et al. 39 observed that when CLL cells were incubated with a protein synthesis inhibitor, cycloheximide, there was a concentration-dependent induction of apoptosis. Furthermore, the combination of a drug that targets RNA transcription (fludarabine or actinomycin D) and a drug that targets protein synthesis (puromycin) seems to be a logical strategy for the effective treatment of patients with CLL. Indeed, the combination of F-ara-A and puromycin resulted in a greater than additive activity against CLL cells in vitro (Figure 7) . Puromycin has been used in the clinical treatment of patients with various types of cancer; an average oral dose of 250-750 mg/day of this drug is well tolerated. 40 Thus, combination of fludarabine and puromycin as a new therapeutic strategy for CLL warrants further evaluation.
It has been reported that activation of CD40 inhibited fludarabine-induced apoptosis in CLL cells. 41, 42 This inhibition is probably by multiple mechanisms. One mechanism is the activation of the NF-kB survival pathway, 41 which mainly involves degradation of the inhibitory factor IkB and may not require new protein synthesis. Thus, inhibition of protein synthesis by fludarabine through depletion of mRNA should not significantly affect NF-kB activation. Another mechanism is the increased expression of the anti-apoptotic Bcl-2 family proteins, 42 which obviously requires new protein synthesis. In this study, CD40 was activated by CD40-ligand or bryostatin-1 1 day before or at the same time with fludarabine incubation. 42 These experimental settings were likely to allow a time window for the synthesis of new protein, because it takes time to deplete the pre-existing mRNA even if fludarabine was present. Thus, the anti-apoptotic protein may still be produced under these conditions. It will be important to test the ability of CD40-ligand or bryostatin-1 to inhibit apoptosis in CLL cells pre-incubated with fludarabine, and to investigate the possibility of enhancing fludarabine activity by inhibiting the actions of NF-kB.
